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Abstract
Background: Lactate clearance, a surrogate for the magnitude and duration of global tissue hypoxia, is used
diagnostically, therapeutically and prognostically. This study examined the association of early lactate clearance
with selected inflammatory, coagulation, apoptosis response biomarkers and organ dysfunction scores in severe
sepsis and septic shock.
Methods: Measurements of serum arterial lactate, biomarkers (interleukin-1 receptor antagonist, interleukin-6,
interleukin-8, interleukin-10, tumor necrosis factor-alpha, intercellular adhesion molecule-1, high mobility group box-
1, D-Dimer and caspase-3), and organ dysfunction scores (Acute Physiology and Chronic Health Evaluation II,
Simplified Acute Physiology Score II, Multiple Organ Dysfunction Score, and Sequential Organ Failure Assessment)
were obtained in conjunction with a prospective, randomized study examining early goal-directed therapy in
severe sepsis and septic shock patients presenting to the emergency department (ED). Lactate clearance was
defined as the percent change in lactate levels after six hours from a baseline measurement in the ED.
Results: Two-hundred and twenty patients, age 65.0 +/- 17.1 years, were examined, with an overall lactate
clearance of 35.5 +/- 43.1% and in-hospital mortality rate of 35.0%. Patients were divided into four quartiles of
lactate clearance, -24.3 +/- 42.3, 30.1 +/- 7.5, 53.4 +/- 6.6, and 75.1 +/- 7.1%, respectively (p < 0.01). The mean levels
of all biomarkers and organ dysfunction scores over 72 hours were significantly lower with higher lactate clearance
quartiles (p < 0.01). There was a significant decreased in-hospital, 28-day, and 60-day mortality in the higher lactate
clearance quartiles (p < 0.01).
Conclusions: Early lactate clearance as a surrogate for the resolution of global tissue hypoxia is significantly
associated with decreased levels of biomarkers, improvement in organ dysfunction and outcome in severe sepsis
and septic shock.
Introduction
The transition from sepsis to severe sepsis and septic
shock is associated with a number of hemodynamic per-
turbations leading to global tissue hypoxia. Global tissue
hypoxia accompanies a myriad of pathogenic mechan-
isms which contribute to the development of the multi-
system organ dysfunction syndrome and increased
mortality [1,2]. Although there is significant interaction
between inflammation, coagulation and organ dysfunc-
tion; a clear cause and effect between global tissue
hypoxia and these molecular processes leading to multi-
organ failure in severe sepsis and septic shock remains
unclear [3].
There is an increasing body of literature establishing
the clinical utility of biomarkers as diagnostic, therapeu-
tic and prognostic indicators in the management of
patients presenting with severe sepsis and septic shock.
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unit (ICU) patient population comprise a mixed picture
of pro-inflammatory, anti-inflammatory, coagulation and
apoptosis biomarker responses [4,5]. However, the dura-
tion of stay for these patients prior to ICU admission
whether on the general hospital ward or emergency
department (ED) can be up to 24 hours [6]. Despite the
abundance of knowledge in the ICU phase of severe
sepsis and septic shock, little is known regarding the
natural history of the biomarkers during the most proxi-
mal stage of disease presentation.
Studies targeting the early detection and eradication of
global tissue hypoxia even after normalization of tradi-
tional vital signs (heart rate, blood pressure and urine
output) have realized significant mortality benefit in
severe sepsis and septic shock [7,8]. As a measure of tis-
sue hypoxia and risk stratification, lactate measurements
have now been incorporated into treatment protocols
and care bundles [9]. We have previously reported that
unresolved global tissue hypoxia reflected by inadequate
lactate clearance during the early phase of resuscitation
implicates organ dysfunction and increased mortality in
severe sepsis and septic shock [10]. The mechanistic
explanation for these observations remains un-eluci-
dated. The purpose of this study is to examine the asso-
ciation of early lactate clearance with the biomarker
activity of inflammation, coagulation, and apoptosis and
the subsequent relationship to organ failure and out-
come in early severe sepsis and septic shock.
Materials and methods
Study Design and Setting
This study is an analysis of biological samples prospec-
tively collected during and after a randomized, con-
trolled study examining early goal-directed therapy for
severe sepsis and septic shock. The study was performed
at Henry Ford Hospital, Detroit, Michigan, and
approved by the Institution Review Board for Human
Research. The details of the original early goal-directed
therapy study protocol have been previously published
[7].
Patient Selection
Patients presenting to the ED of an urban academic ter-
tiary care hospital from March 1997 to March 2001
were consented if they met enrollment criteria. Patients
were included if they had 1) a source of infection sus-
pected by the treating physician; 2) at least two of four
systemic inflammatory response syndrome (SIRS) cri-
teria [11]; and 3) either systolic blood pressure less than
90 mm Hg after a 20-30 ml/kg crystalloid fluid bolus or
lactate greater than or equal to 4 mmol/L. Patients were
excluded if they had age less than 18 years, pregnancy,
acute cerebral vascular event, acute coronary syndrome,
acute pulmonary edema, status asthmaticus, dysrhyth-
mia as a primary diagnosis, contraindication to central
venous catheterization, active gastrointestinal hemor-
rhage, seizure, drug overdose, burn injury, trauma,
requirement for immediate surgery, uncured cancer,
immunocompromised state, or do-not-resuscitate status.
After meeting enrollment criteria, patients were invited
to participate in the randomized protocol comparing
early goal-directed therapy versus standard care and/or
provide blood samples for serial biomarker
measurements.
Data Collection
Patient demographics, hemodynamic variables, labora-
tories, sources of infection, comorbidities, and outcome
were collected at baseline. Simultaneous measurements
of serum arterial lactate, biomarkers and organ dysfunc-
tion scores were obtained at time 0, 6, 12, 24, 36, 48, 60
and 72 hours after enrollment. Therapeutic interven-
tions, such as antibiotics, fluids, packed red cells transfu-
sion, vasoactive agents, and mechanical ventilation,
given in the ED and up to 72 hours were recorded.
Information required for the Acute Physiology and
Chronic Health Evaluation (APACHE) II, Simplified
Acute Physiology Score (SAPS) II, Multiple Organ Dys-
function Score (MODS), and Sequential Organ Failure
Assessment (SOFA) score calculations were obtained at
each time point. Patients were followed until in-hospital
death or up to 60 days after enrollment.
Biomarker Assays
Biomarkers were chosen to represent pro-inflammatory,
anti-inflammatory, coagulation, and apoptosis pathways
involved in the pathogenesis of severe sepsis and septic
shock. Analysis of the biomarkers for the purpose of
this study was performed from September 2003 to
December 2004. The pro-inflammatory biomarkers
included interleukin-6 (IL-6), interleukin-8 (IL-8), tumor
necrosis factor-a (TNF-a), intercellular adhesion mole-
cule-1 (ICAM-1), and high mobility group box-1
(HMGB-1). Anti-inflammatory biomarkers included
interleukin-1 receptor antagonist (IL-1ra) and interleu-
kin-10 (IL-10). Coagulation and apoptosis biomarkers
included D-Dimer and caspase-8, respectively. Biomar-
ker assays were performed by Biosite Inc, San Diego,
California. Assays were performed using immunometric
(sandwich) assays with NeutrAvidin-coated 384-well
block microtiter plates (Pierce Biotechnology, Rockford,
IL) and a Genesis RSP 200/8 Workstation (Tecan U.S.,
Durham, NC). Each sample was tested in duplicate.
Before the assays, biotinylated primary antibody was
diluted in assay buffer containing 10 mmol/L trishydrox-
ymethylaminomethane HCl (pH 8.0), 150 mmol/L
sodium chloride, 1 mmol/L magnesium chloride, 0.1
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(9-10 kDa). The concentration of biotinylated antibody
was predetermined by titration. The primary antibody
(10 μL per well) was added to the plates and incubated.
After washing, 10 g/L bovine serum albumin and 1 g/L
sodium azide were added to the plate wells, which were
then incubated at room temperature. Next, the plates
were washed three times with borate-buffered saline
containing 0.02% polyoxyethylene (20) sorbitan mono-
laurate (BBS-Tween).
For each sample, 10 μL aliquots were added to each
plate well and the plates were incubated. Following this
incubation, the plates were washed three times and alka-
line phosphatase-conjugated antibody (10 μL per well)
was added to each plate well and further incubated. The
concentration of the alkaline phosphatase-conjugated
antibody was predetermined to ensure a linear profile in
the dynamic range of interest. After additional incuba-
tion, the plates were washed nine times with BBS-Tween.
AttoPhos substrate (S1011, Promega, Madison, WI), a
fluorescence-enhancing substrate previously diluted in
AttoPhos buffer (S1021, Promega), was then added to aid
in the measurement of the activity of antibody-conju-
gated alkaline phosphatase bound in each well. The
plates were then scanned in a fluorometer (Tecan Spec-
trafluor, Tecan U.S.) using an excitation wavelength of
430 nm and an emission wavelength of 570 nm. Each
well was scanned 6 times at 114-sec intervals, and the
rate of fluorescence generation was calculated. Calibra-
tion curves were derived from eight points tested at mul-
t i p l el o c a t i o n so nt h ea s s a yp l a t eu s i n ga4 - p a r a m e t e r
logistic fit, from which sample concentrations were sub-
sequently calculated. Each plate included calibration
wells consisting of multiple analyte concentrations and
control samples. Calibration curves for each biomarker
assay were generated for IL-1ra (150-30,000 pg/mL), IL-6
(20-10,000 pg/mL), IL-8 (15-3,000 pg/mL), IL-10 (15-
1,000 pg/mL), TNF-a (20 -2,000 pg/mL), ICAM-1 (2.5-
900 ng/mL), HMGB-1 (0.5-100 ng./mL), D-Dimer (0.5-
40 μg/mL), and caspase-3 (0.1-200 ng/mL).
Patient Stratification
Lactate clearance was defined as the percent change in
lactate level after six hours from a baseline measure-
ment. It is calculated by using the following formula:
lactate at ED presentation (hour 0) minus lactate at
hour 6, divided by lactate at ED presentation, then mul-
tiplied by 100. A positive value denotes a decrease or
clearance of lactate, whereas a negative value denotes an
increase in lactate after 6 hours of intervention.
Lactate clearance
LactateED Presentation LactateHour 

 () 6 10 00
LactateED Presentation
The study population was sorted by increasing lactate
clearance and divided into four groups with equivalent
number of patients for comparisons among lactate clear-
ance quartiles.
Statistical Analysis
For the purpose of this study, lactate clearance, biomar-
kers and organ dysfunction scores were analyzed in all
patients enrolled in the study, irrespective of the treat-
ment group assigned to the patients. We a priori
accepted that lactate clearance is a reflection of the
therapies received by the patients, such as fluids, red
cells transfusion, vasopressors, and inotrope; rather than
a function of the randomization assignment to early
goal-directed therapy or standard care. Descriptive sta-
tistics were used to summarize patient characteristics.
The Kruskal-Wallis test was used to compare numeric
variables (e.g., vital signs, hemodynamic variables,
laboratories, biomarker measurements, and organ dys-
function scores over 72 hours) among patients stratified
by lactate clearance quartiles. The standard Chi-square
test was used to compare categorical variables (e.g., sep-
tic shock, culture status, and therapeutic interventions)
among the lactate clearance quartiles. Mortality out-
comes were compared among the lactate clearance
quartiles using Chi-square analysis, with Kaplan-Meier
estimation used to obtain mortality rates up to 12
months. A two-tailed p-value less than 0.05 was consid-
ered statistically significant. Data are presented as per-
centage or mean ± standard deviation.
Results
Two hundred and twenty-two patients, age 65.0 ± 17.1
years, were enrolled within 1.6 ± 2.1 hours of ED pre-
sentation. The initial hemodynamic parameters included
central venous pressure of 5.1 ± 8.5 mm Hg, mean
arterial pressure 74.8 ± 25.7 mm Hg, central venous
oxygen saturation 49.2 ± 12.6 percent, and lactate 7.4 ±
4.6 mmol/L. Fifty-five percent of patients had septic
shock, 37.1% had blood culture positive, and the most
common source of infection was pneumonia. Lactate
clearance was 35.5 ± 43.1 percent and in-hospital mor-
tality rate 35.0% (Table 1).
The lactate clearance quartiles were -24.3 ± 42.3, 30.1
± 7.5, 53.4 ± 6.6, and 75.1 ± 7.1%, respectively (p <
0.01, Table 2). There was no significant difference
among the lactate clearance quartiles with respect to
age, demographics, co-morbidities, blood culture posi-
tive, hemodynamic variables, baseline lactate, and other
laboratories (except platelets, total bilirubin and albu-
min). There was significant difference in the number of
septic shock patients among the lactate clearance quar-
tiles, with the highest percent of septic shock patients
in the lowest clearance quartile (p < 0.01). Quartiles
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vasopressor and mechanical ventilation during the first
6 hours. After 6 hours, only vasopressor remained sig-
nificantly higher in lower lactate clearance quartiles
(Table 3).
The mean levels of all biomarkers averaged over 72
hours were significantly lower with higher lactate clear-
ance quartiles (Table 4, Figure 1). Similarly, the mean
organ dysfunction scores averaged over 72 hours were
significantly lower with higher lactate clearance quartiles
(Table 4, Figure 2).
There was significant decreased in-hospital, 28-day
and 60-day mortality for higher lactate clearance quar-
tiles (Table 4). Kaplan-Meier survival analysis showed a
survival benefit over 12 months for patients in the
higher lactate clearance quartiles (Figure 3).
Discussion
The current pathogenesis of severe sepsis and septic
shock is described as a complex interaction of pro- and
anti-inflammation, coagulation, and apoptosis triggered
by the infecting microorganism. The bacteria outer
membrane lipopolysaccharide molecule (LPS, endotoxin)
activates a toll-like receptor 4 (TLR-4) signaling pathway
that results in translocation of nuclear factor-B( N F -
B) and production of inflammatory cytokines. The
result is a production of pro-inflammatory cytokines
that are balanced by an array of anti-inflammatory cyto-
kines. The coagulation pathway is also activated by LPS-
mediated signaling and further regulated by the cyto-
kines, inducing the production of tissue factor, pro-
thrombin conversion to thrombin, and fibrin
production. Fibrinolysis is impaired due to increased
production of plasminogen-activator inhibitor type-1
(PAI-1), decreased generation of plasmin and reduced
removal of fibrin. The procoagulant state further down
regulates the anticoagulant proteins, antithrombin, pro-
tein C, and tissue factor pathway inhibitor. The net
result is deposition of fibrin clots throughout the
endothelium, resulting in inadequate blood flow, organ
hypoperfusion, global tissue hypoxia and cell death
[3,12].
Clinically, lactate has been studied as a measure of ill-
ness severity in circulatory shock for several decades
dating back to the 1800’s [13,14]. Although there are
Table 1 Patient characteristics.
No. Patients 220
Age (years) 65.0 ± 17.1
Male:Female (%) 54.1:45.9
Time from ED arrival to enrollment (hours) 1.6 ± 2.1
Length of hospital stay (days) 13.9 ± 16.6
Vital signs and hemodynamic variables
Temperature (°C) 36.3 ± 2.8
Heart rate (beats per min) 117.1 ± 30.1
Systolic blood pressure (mm Hg) 107.5 ± 36.2
Mean arterial pressure (mm Hg) 74.8 ± 25.7
Shock index (heart rate/systolic blood pressure) 1.2 ± 0.5
Respiratory rate (breaths per min) 31.5 ± 11.1
CVP (mm Hg) 5.1 ± 8.5
ScvO2 (%) 49.2 ± 12.6
Laboratories
White blood cells (×10
3 per mm
3) 14.0 ± 9.0
Hemoglobin (g/dL) 11.4 ± 2.7
Platelets (×10
3 per μL) 211.5 ± 122.0
Creatinine (mg/dL) 2.9 ± 2.0
Glucose (mg/dL) 259.4 ± 327.8
Anion gap (mEq/L) 21.5 ± 8.0
Total bilirubin (mg/dL) 1.5 ± 2.1
Albumin (g/dL) 2.8 ± 0.7
Lactate (mmol/L) 7.4 ± 4.6
Lactate clearance (%) 35.5 ± 43.1
Septic shock (%) 55.0
Culture positive (%) 65.6
Blood culture positive (%) 37.1
Organ dysfunction scores
APACHE II 21.5 ± 7.0
SAPS II 49.8 ± 11.0
MODS 7.6 ± 3.1
SOFA 6.5 ± 2.9
Source of infection (%)
Pneumonia 39.5
Urinary tract infection 13.2
Intra-abdominal 4.1
Other 43.2
Comorbidities (%)
Chronic obstructive pulmonary disease 16.4
Chronic renal insufficiency 20.9
Congestive heart failure 30.9
Coronary artery disease 22.7
Diabetes mellitus 30.5
Hypertension 67.3
Liver disease 21.4
Outcome (%)
In-hospital mortality 35.0
28-day mortality 36.4
60-day mortality 42.7
Vital signs, hemodynamic variables, laboratories and organ dysfunction scores
represent baseline values at patient enrollment. ED - emergency department;
CVP - central venous pressure; ScvO2 - central venous oxygen saturation;
Acute Physiology and Chronic Health Evaluation (APACHE) II; Simplified Acute
Physiology Score (SAPS) II; Multiple Organ Dysfunction Score (MODS);
Sequential Organ Failure Assessment (SOFA).
Nguyen et al. Journal of Inflammation 2010, 7:6
http://www.journal-inflammation.com/content/7/1/6
Page 4 of 11Table 2 Patient characteristics, basline vital signs, hemodynamics and laboratories by lactate clearance quartile.
Quartile 1
N=5 5
Quartile 2
N=5 5
Quartile 3
N=5 5
Quartile 4
N=5 5
P-value
Lactate clearance (%) - 24.3 ± 42.3 30.1 ± 7.5 53.4 ± 6.6 75.1 ± 7.1 <0.01
Age (years) 63.2 ± 16.5 68.2 ± 17.5 65.7 ± 15.7 66.7 ± 18.4 0.29
Septic shock (%) 70.9 58.2 54.6 36.4 <0.01
Culture positive (%) 45.5 33.3 42.6 32.7 0.41
Blood culture positive (%) 43.4 34.0 42.3 28.9 0.36
Vital signs and hemodynamics
Temperature (°C) 36.3 ± 3.0 36.5 ± 3.2 36.1 ± 2.7 36.4 ± 2.5 0.67
Heart rate (beats per min) 113.8 ± 25.4 117.0 ± 27.6 120.0 ± 30.9 117.8 ± 36.0 0.70
Systolic blood pressure (mm Hg) 108.0 ± 39.7 103.3 ± 30.2 108.1 ± 35.0 110.4 ± 40.0 0.88
Mean arterial pressure (mm Hg) 76.1 ± 26.6 71.2 ± 21.8 75.8 ± 26.9 76.1 ± 27.4 0.81
Shock index (HR/SBP) 1.2 ± 0.5 1.2 ± 0.4 1.2 ± 0.5 1.2 ± 0.6 0.76
Respiratory rate (breaths per min) 29.5 ± 10.3 30.4 ± 10.9 34.2 ± 11.8 32.2 ± 10.9 0.16
CVP (mm Hg) 6.0 ± 8.7 4.5 ± 8.7 3.9 ± 8.9 5.7 ± 8.2 0.16
ScvO2 (%) 49.3 ± 12.9 51.4 ± 12.0 44.1 ± 12.6 51.2 ± 12.3 0.28
Laboratories
White blood cells (×10
3 per mm
3) 11.8 ± 7.1 13.5 ± 8.9 15.0 ± 10.5 15.6 ± 9.1 0.13
Hemoglobin (g/dL) 11.6 ± 2.6 11.0 ± 2.9 11.5 ± 2.5 11.3 ± 2.7 0.68
Platelets (×10
3 per μL) 163.7 ± 82.2 184.0 ± 116.7 254.1 ± 135.6 244.4 ± 124.8 <0.01
Creatinine (mg/dL) 2.5 ± 2.2 2.5 ± 1.7 2.6 ± 1.9 2.7 ± 2.4 0.94
Glucose (mg/dL) 303.5 ± 421.4 172.1 ± 150.6 240.9 ± 275.0 321.1 ± 382.0 0.07
Anion gap (mEq/L) 22.2 ± 9.6 20.0 ± 7.3 21.5 ± 7.9 22.2 ± 6.9 0.52
Total bilirubin (mg/dL) 1.9 ± 2.3 1.9 ± 3.1 1.2 ± 1.4 0.9 ± 0.7 0.03
Albumin (g/dL) 2.7 ± 0.7 2.8 ± 0.7 2.8 ± 0.7 3.1 ± 0.6 <0.01
Lactate (mmol/L) 7.5 ± 5.8 7.3 ± 4.9 7.3 ± 3.8 7.3 ± 3.5 0.47
Lactate clearance - defined as the percent change in lactate level after six hours from baseline measurement = [(Lactate
ED Presentation - Lactate
Hour 6)/Lactate
ED
Presentation] × 100. A positive value denotes a decrease or clearance of lactate, whereas a negative value denotes an increase in lactate after 6 hours of
intervention. Lactate clearance quartile - derived from sorting the study population by increasing lactate clearance and separating into four groups with
equivalent number of patients. HR - heart rate; SBP - systolic blood pressure; CVP - central venous pressure; ScvO2 - central venous oxygen saturation.
Table 3 Therapies during the first 6 hours in the ED and from 7 to 72 hours in the ICU by lactate clearance quartile.
Quartile 1
N=5 5
Quartile 2
N=5 5
Quartile 3
N=5 5
Quartile 4
N=5 5
P-value
Therapies in first 6 hours
Antibiotics (%) 72.2 77.5 72.1 75.0 0.95
Appropriate Antibiotics (%) 86.3 77.5 90.7 88.9 0.59
Fluids (mL) 4531.2 ± 2745.3 4263.5 ± 2872.9 4266.8 ± 3449.5 3741.7 ± 3136.4 0.27
Transfusion (%) 54.6 41.8 26.4 43.6 0.27
Vasopressor (%) 50.9 36.4 27.3 14.6 <0.01
Inotrope/dobutamine (%) 5.5 3.6 9.1 12.7 0.29
Mechanical ventilation (%) 74.6 50.9 58.2 38.2 <0.01
Therapies from 7 to 72 hours
Antibiotics (%) 95.0 93.9 100 97.0 0.50
Fluids (mL) 8817.2 ± 5818.1 9666.7 ± 6555.2 10329.8 ± 6866.6 7141.9 ± 4097.8 0.06
Transfusion (%) 23.6 20.0 20.0 27.3 0.77
Vasopressor (%) 47.3 47.3 30.9 18.2 <0.01
Inotrope/dobutamine (%) 10.9 14.6 9.1 12.7 0.83
Mechanical ventilation (%) 12.7 14.6 7.3 7.3 0.48
Lactate clearance quartile - derived from sorting the study population by increasing lactate clearance and separating into four groups with equivalent number of
patients.
Nguyen et al. Journal of Inflammation 2010, 7:6
http://www.journal-inflammation.com/content/7/1/6
Page 5 of 11various explanations regarding the mechanisms respon-
sible for lactate accumulation in severe sepsis and septic
shock, it remains a robust surrogate marker for the
development of multi-organ failure and poor outcome
[15-19]. Similar observations have been noted in other
conditions of critical illness, including pediatric and
adult cardiac surgery [20-22], the post-resuscitation per-
iod of cardiac arrest [23,24], trauma [25], general surgi-
cal [26], and liver surgery patients [27]. A recurring
theme in these studies is the inflammatory response
plays a crucial mechanistic intermediate between lactate
clearance and the development of multi-organ failure.
Evidence-based guidelines have recommended that an
elevated lactate is sufficient to diagnosis shock, irrespec-
tive of hypotension [28]. Sepsis with lactate level greater
than or equal to 4 mmol/L is associated with high mor-
tality and is an indication to initiate treatment protocols
and care bundles [7,9,29]. We previously reported a sig-
nificant inverse relationship between lactate clearance
(or resolution of global tissue hypoxia) during the first 6
hours and mortality in severe sepsis and septic shock
[ 1 0 ] .W eh a v ea l s os h o w nt h a tearly goal-directed ther-
apy targeting global tissue hypoxia to be more effective
than standard care in decreasing lactate during the first
six hours of intervention [7]. In this study, we found a
significant association between improving lactate
clearance in the first 6 hours and a corresponding
decrease in mean biomarker levels over 72 hours. This
potential mechanistic link was also positively associated
with improved organ dysfunction scores and decreased
mortality.
The association between poor lactate clearance and
the need for vasopressor therapy is consistent with
observations that pathogenic but reversible correlates of
outcome may be established in the first few hours of
disease presentation. A limited course of vasopressor
therapy indicates reversible tissue hypoxia; however,
prolonged vasopressor usage for hemodynamic support
is associated with worse lactate clearance and thus out-
come [30]. Additionally, lactate clearance has been
shown to be significantly associated with improved
microcirculatory flow [31]. This provides supportive evi-
dence for the mechanistic connection between pro-
longed vasopressor use, tissue ischemia, persistent
lactate elevation, morbidity and mortality. Our results
further support the notion that tissue hypoxia plays a
crucial role in the early complex mechanisms leading to
the endothelial response in severe sepsis and septic
shock, rather than a terminal or irreversible event fol-
lowing inflammation and coagulopathy [1]. Thus a goal-
directed hemodynamic optimization strategy targeting
the resolution of global tissue hypoxia, reflected by
Table 4 Biomarker levels and organ dysfunction scores averaged over 72 hours by lactate clearance quartile.
Quartile 1
N=5 5
Quartile 2
N=5 5
Quartile 3
N=5 5
Quartile 4
N=5 5
P-value
Biomarkers over 72 hours
IL-1ra (ng/mL) 8455.9 ± 8838.4 7565.4 ± 8289.1 6421.3 ± 7957.5 2792.6 ± 3635.7 <0.01
IL-6 (pg/mL) 2839.5 ± 3487.0 2680.1 ± 3174.0 2426.7 ± 3269.4 663.2 ± 1583.5 <0.01
IL-8 (pg/mL) 480.3 ± 802.4 355.3 ± 559.1 356.3 ± 735.1 76.4 ± 218.0 <0.01
IL-10 (pg/mL) 303.6 ± 298.7 227.4 ± 218.5 180.2 ± 243.4 85.4 ± 121.9 <0.01
TNF-a (pg/mL) 65.2 ± 105.9 50.9 ± 69.2 47.4 ± 72.8 19.6 ± 19.8 <0.01
ICAM-1 (ng/mL) 409.1 ± 208.1 413.3 ± 204.5 379.7 ± 213.8 299.2 ± 156.1 <0.01
HMGB-1 (ng/mL) 4.6 ± 8.3 5.0 ± 10.4 2.5 ± 3.3 1.6 ± 2.4 <0.01
D-Dimer (μ/mL) 20.8 ± 9.5 18.9 ± 9.5 18.1 ± 8.9 15.7 ± 9.7 0.04
Caspase-3 (ng/mL) 3.8 ± 7.5 2.4 ± 3.8 1.9 ± 2.6 1.1 ± 0.8 <0.01
Organ dysfunction over 72 hours
APACHE II 16.8 ± 6.3 16.6 ± 6.4 14.8 ± 6.9 11.6 ± 6.0 <0.01
SAPS II 43.9 ± 12.4 44.6 ± 43.5 39.5 ± 12.0 34.2 ± 11.9 <0.01
MODS 8.0 ± 3.5 7.0 ± 4.0 5.7 ± 4.2 3.4 ± 2.5 <0.01
SOFA 8.8 ± 3.3 8.0 ± 3.4 6.8 ± 4.3 4.4 ± 2.7 <0.01
Outcome (%)
In-hospital mortality 52.7 41.8 29.1 16.4 <0.01
28-day mortality 54.9 49.0 33.5 21.6 <0.01
60-day mortality 63.1 52.9 38.0 33.6 0.01
Lactate clearance quartile - derived from sorting the study population by increasing lactate clearance and separating into four groups with equivalent number of
patients. IL-1ra - interleukin-1 receptor antagonist; IL-6 - interleukin-6; IL-8 - interleukin-8; IL-10 - interleukin-10; TNF-a - tumor necrosis factor-a; ICAM-1 -
intercellular adhesion molecule-1; HMGB-1 - high mobility group box-1; Acute Physiology and Chronic Health Evaluation (APACHE) II; Simplified Acute Physiology
Score (SAPS) II; Multiple Organ Dysfunction Score (MODS); Sequential Organ Failure Assessment (SOFA).
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endothelial and microcirculatory dysfunction in patients
who most likely will benefit [2].
In-vitro models have shown that hypoxia induces the
pro-inflammatory cytokines, IL-1, IL-6, IL-8, and TNF-
a [32-36]. These cytokines then increase the expres-
sion of intercellular adhesion molecules (ICAM-1) and
further activation and migration of neutrophils [37-39].
In humans, IL-6 and IL-8 elevations correlated signifi-
cantly to lactate levels (as a measure of tissue hypoxia)
in sepsis [40,41]. Recently, combined serial lactate and
cytokine levels (IL-1, IL-6, IL-10, and HMGB-1) in
septic shock patients were shown to be useful indica-
tors of clinical outcome [42,43]. In our study, IL-1ra,
IL-6, IL-8, IL-10, and TNF-a were measured due to
their close association with the early pro- and anti-
inflammatory response. HMGB-1 was chosen as a pro-
inflammatory mediator that appears much later than
the other cytokines after LPS stimulation [44]. We
have shown that the higher lactate clearance in the
IL-6
IL-8
TNF-
ICAM-1
HMGB-1
0
100
200
300
400
500
550
1050
1550
2050
2550
3050
0
1
2
3
4
5
6
25
35
45
55
65
75
Lactate
clearance
quartile
123
4
I
L
-
6
 
(
p
g
/
m
L
)
I
L
-
8
 
(
p
g
/
m
L
)
I
C
A
M
-
1
 
(
n
g
/
m
L
)
T
N
F
-
 
(
p
g
/
m
L
)
H
M
G
B
-
1
 
(
n
g
/
m
L
)
IL-1ra
IL-10
D-Dimer
Caspase-3
50
100
150
200
250
300
350
1000
3000
5000
7000
9000
0
1
2
3
4
5
10
15
20
25
Lactate
clearance
quartile
1
2
3
4
I
L
-
1
r
a
 
(
n
g
/
m
L
)
I
L
-
1
0
 
(
p
g
/
m
L
)
D
-
D
i
m
e
r
 
(
/
m
L
)
C
a
s
p
a
s
e
-
3
 
(
n
g
/
m
L
)
1A. Pro-inflammatory markers
1B. Anti-inflammatory, coagulation, and apoptosis markers
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Page 7 of 11first 6 hours, the greater the decrease in all pro-inflam-
matory and anti-inflammatory cytokines measured over
72 hours.
Hematologic abnormalities (leukocytotosis, anemia
and thrombocytopenia) are common in severe sepsis
and septic shock. Alterations in the levels of various
mediators of coagulation and fibrinolysis have been
reported to be associated with disseminated intravascu-
lar coagulation (DIC) and mortality [45]. Patients with
SIRS and sepsis having DIC were shown to have higher
serial lactate levels over 4 days compared to those
patients without DIC, suggesting a pathogenic link
between tissue hypoxia and intravascular coagulation
[46]. While no single marker measured at hospital
admission is sufficiently sensitive or specific in diagnos-
i n gD I C ,w ec h o s et om e a s u r eD - D i m e ra sam a r k e ro f
coagulation in this study as it is widely available, a cor-
relate to the pro-inflammatory cytokine levels, and a
valuable screening marker for organ failure and mortal-
ity [47-49]. It also has been used previously as an
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Page 8 of 11indicator of response to therapies such as recombinant
human activated protein C in severe sepsis [50]. In our
study, we showed that improvements in coagulation
(reflected by a decrease in D-Dimer levels over 72
hours) corresponded with lactate clearance during the
first 6 hours. Our results provide further evidence that
t i s s u eh y p o x i am a yb eap r e c e d i n go rp a r a l l e le v e n tt o
the pro-coagulant state in severe sepsis and septic
shock, and therapies targeting tissue hypoxia may play a
crucial role in reversing this coagulopathy.
Cell death through apoptosis is a highly regulated pro-
cess in the presence or absence of inflammation [51].
Apoptosis is initiated by two pathways: 1) a receptor
activated, caspase-8 mediated (extrinsic) pathway; and 2)
a mitochondrial initiated caspase-9 mediated (intrinsic)
pathway. Either of these caspases can activate caspase-3
in the common pathway resulting in final cell death.
Caspases are pro-apoptotic proenzymes that inactivate
protective proteins and contribute to cell death by direct
cellular disassembly via cell shrinkage (pyknosis) and
nuclear fragmentation (karyorrhexis) [52]. The regula-
tion of apoptosis in sepsis is complex, as the infecting
pathogen may inhibit or induce apoptosis, involving
both the extrinsic and intrinsic pathways, to enhance its
damaging effects to the host [53]. Caspase activation in
a p o p t o s i si sa ne n e r g y - d e p e ndent process. Hypoxia can
induce apoptosis as long as cells have an adequate
amount of adenosine triphosphate. Previously, apoptosis
was believed to occur via the intrinsic pathway with
cytochrome c release and caspase-9 activation in oxy-
gen-deprived cells [54]. However, the extrinsic pathway
may also play an important role in oxidative stress
induced apoptosis [53]. In this study, caspase-3 as a
marker of the final common pathway in apoptosis was
shown to be elevated over 72 hours in patients with
decreased lactate clearance, compared to lower caspase-
3 in patients with higher lactate clearance. This finding
supports the premise that tissue hypoxia in severe sepsis
and septic shock is associated with increased apoptosis,
suggesting that the ill effects resulting in cell death may
be mitigated by resolution of global tissue hypoxia.
Our results provide evidence that the design and
interpretation of future clinical trials should consider
the early stages of severe sepsis and septic shock. Pre-
viously, two studies failed to show significant outcome
benefit with inhibition of TNF-a and IL-1ra in severe
sepsis and septic shock patients enrolled in the ICU
[55,56]. The association of lactate clearance with these
targeted biomarkers shown in our study suggests that
the severity of tissue hypoxia should be part of patient
selection criteria in studies examining novel therapies
that may alter its down stream effects. The failure to
consider the magnitude, duration of tissue hypoxia and
the timing of patient enrollment in clinical trials will
likely result in some degree of hemodynamic heteroge-
neity confounding any treatment effect [57].
The results of our study do not confirm a causal rela-
tionship, but an association between lactate clearance in
the first 6 hours and biomarker response over 72 hours.
High lactate clearance quartiles had fewer patients in sep-
tic shock obviously requiring less vasopressor usage, but
no difference in antibiotic and fluid administration. Lactate
clearance over 6 hours may also depend on the patient’s
underlying comorbidities, such as liver disease, and the
disease process rather than solely on the therapies them-
selves. However, baseline demographics, comorbidities,
lactate and hemodynamic variables were similar in all
quartiles. Thus the ability to clear lactate irrespective of
the mechanism and its association with improved biomar-
kers suggests that further studies are needed to examine
global tissue hypoxia as an inciting factor in the patho-
genic pathways of severe sepsis and septic shock. Which
of the three pathogenic pathways predominate as an asso-
ciation to tissue hypoxia cannot be discerned by this
exploratory study. Nonetheless, our observation of a signif-
icant correlation of lactate clearance and decrease mortal-
ity is consistent with previous studies.
We have previously shown that early goal-directed
therapy is significantly more effective than standard
therapy in decreasing lactate (by 44% compared to 29%,
p < 0.01) during the first 6 hours, resulting in improved
organ dysfunction and mortality [7]. We further showed
that global tissue hypoxia and early goal-directed ther-
apy were associated with distinct biomarker patterns
that were evident as early as 3 hours after intervention
[2]. The purpose of this study was to show that lactate
clearance is associated with improved biomarkers and
organ dysfunction scores. We a priori chose not to dis-
tinguish lactate clearance, biomarker responses, and
organ dysfunction scores by resuscitation groups. While
we have shown that lactate clearance is a mechanistic
link in the early pathogenesis of sepsis, these findings do
not support the substitution of lactate clearance as an
independent alternative to an organized hemodynamic
optimization strategy such as early goal-directed therapy.
Conclusions
This study showed a significant association between lac-
tate clearance and biomarkers of pro- and anti-inflam-
mation, coagulation, apoptosis; and further with multi-
organ dysfunction and mortality in severe sepsis and
septic shock. These findings support a growing body of
evidence suggesting that global tissue hypoxia plays a
crucial role in the complex mechanisms leading to the
endothelial response in severe sepsis and septic shock
rather than a terminal event. Future studies examining
the pathogenic mechanisms or novel therapies for
severe sepsis and septic shock should include lactate
Nguyen et al. Journal of Inflammation 2010, 7:6
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Page 9 of 11clearance as a measure of prognosis and therapeutic
responses.
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